1. Changes in fecal flora and comparative multiple-dose pharmacokinetics of ceftibuten, cefpodoxime proxetil and amoxycillin/clavulanate 
Jörg Hamacher, Jörg Luepke, Bruce E. Reidenberg, Carl Erik Nord, Klaus Borner, Peter Koeppe, David Bristol, Hartmut Lode 
Clinical Microbiology and Infection 
Volume 5, Issue 6, Pages (June 1999)
DOI: /j tb00153.x
Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions

2. Figure 1A
Ceftibuten. Fecal microorganisms of the 18 volunteers, with median value of microorganisms per gram feces and regression (–) during the study periods. The study drug administration was from day 0 to day 7. The results of two stool samples collected in the week before each study drug administration as well as of samples during study drug administration on days 4, 7, and 8 and during the ‘washout periods’ on days 12, 21 and 28 are shown.
Clinical Microbiology and Infection 1999 5, DOI: ( /j tb00153.x)
Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions

3. Figure 1B
Cefpodoxime. Fecal microorganisms of the 18 volunteers, with median value of microorganisms per gram feces and regression (–) during the study periods The study drug was from day 0 to day 7. The results of two stool samples collected in the week before each study drug administration as well as of samples during study drug administration on days 4, 7, and 8 and during the washout periods on days 12, 21 and 28 are shown.
Clinical Microbiology and Infection 1999 5, DOI: ( /j tb00153.x)
Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions

4. Figure 1C
Amoxycillin/clavulanate. Fecal microorganisms of the 18 volunteers, with median value of microorganisms per gram feces and regression (–) during the study periods. The study drug administration was from day 0 to day 7. The results of two stool samples collected in the week before each study drug administration as well as of samples during study drug administration on days 4, 7, and 8 and during the ‘washout periods’ on days 12, 21 and 28 are shown.
Clinical Microbiology and Infection 1999 5, DOI: ( /j tb00153.x)
Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions

5. Figure 2
Serum regression (–), median of cis-ceftibuten and trans-ceftibuten (•) and standard range in serum after oral 400 mg ceftibuten every 24 h in 18 volunteers on day 1. Values are normalized to a body weight of 70 kg.
Clinical Microbiology and Infection 1999 5, DOI: ( /j tb00153.x)
Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions

6. Figure 3
Serum concentrations (median and standard ranges) on day 1 and day 7; regression and simulation based on day 1 data with oral 400 mg ceftibuten every 24 h in 18 volunteers. Values are normalized to a body weight of 70 kg. τ = time between two drug administrations.
Clinical Microbiology and Infection 1999 5, DOI: ( /j tb00153.x)
Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions

7. Figure 4
Serum concentrations (median and standard ranges) on day 1 and day 7, regression and simulation based on day 1 data with oral 400 mg cefpodozime proxetil every 12 h in 18 volunteers. Values are normalized to a body weight of 70 kg. τ = time between two drug administrations.
Clinical Microbiology and Infection 1999 5, DOI: ( /j tb00153.x)
Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions

8. Figure 5
Serum regression (–) of amoxycillin 500 mg every 8 h and clavulanate 125 mg every 8 h (median and standard ranges) in 18 volunteers on day 1. Values are standardized to a body weight of 70 kg.
Clinical Microbiology and Infection 1999 5, DOI: ( /j tb00153.x)
Copyright © 1999 European Society of Clinical Infectious Diseases Terms and Conditions